At the Silver Institute, we now do personalized molecular testing to determine which chemotherapy, natural substances, and immunotherapy works on your cancer. What this means to you is that we can determine, doing sophisticated molecular testing, what exact treatment is needed to kill your cancer. We no longer have to rely on statistical analysis to pick chemo which may or may not work on the patient.
Chemosensitivity testing provides the best information and guidance about the treatment and in particular what treatment may be best suited to the individual in clinical practice.Read More
The lab we use identifies tumor cells and isolates them from the samples for the following analysis:
- Viability testing of chemotherapy drugs.
- Genetic profiling for guidance about target therapies, such as monoclonal antibodies.
- Viability testing and identification of mechanisms of action, of natural substances which may be used as part of the complimentary treatment strategy.
W use a specialized lab composed of the most advanced and innovative technology that focuses on Molecular Oncology. They offer several different tests that are used for:
- The early detection and diagnosis of new cancers
- Monitoring of existing cancers
- Prognosis about the risk of recurrence of previous cancers
- The best of alternative and traditional therapy.
What Does Molecular Oncology Measure?
Unlike other tests, the genetic cancer testing we use is a very sensitive test that allows isolation and counting of circulating tumor cells in the blood sample. These are cancer cells that have broken away from the primary tumor and have entered the bloodstream.
The lab also evaluates genetic markers, 72 related genes, on the tumor cell to predict outcomes of treatment and prognosis. In addition, it can provide the following information:
- A count of circulating tumor cells present in the bloodstream which indicates tumor burden.
- Identification of several specific types of cancer. Approximately 95% of the time when markers are positive, they can identify melanoma and sarcoma cancers, and the site of origin for kidney and prostate cancers.
- Chemo sensitivity testing, identification of chemotherapy drugs that demonstrate the most effective kill rate to a person’s individual cancer cells.
- Identification of chemo resistance that is identification of chemotherapy drugs that will not be as effective for treatment.
- Assessment of natural substances and plant extracts for potency against the cancers isolated circulating tumor cells.
- Identification of immune factors and metastatic risk.
- Test for all cancers with circulating tumor cells and cancer stem cells.
- Data on how an individual will react to a specific chemotherapy agent. An individual’s genetic makeup determines whether they are accumulators or rapidly metabolized as certain drugs. This can play a critical role in determining how effective a specific drug treatment is likely to be, and how significant the side- effects will be.
- Tests for 72 tumor related genes and 4 resistant factors that can be used by physicians to determine the nature and aggressiveness to cancer.
- Identification of specific markers of the tumor cells to assist the physician in forming a targeted approach.
No two cancers are alike even within an individual patient. Tumors may change over time. We are moving away from the concept that all cancers are the same. There is a new consensus that to truly fight cancer doctors need to understand it from the inside out, which means decoding its DNA and evaluate the biomarkers.
Until recently this highly sophisticated approach to cancer was virtually nonexistent. But fast moving developments in genetics and molecular biology are quickly changing that. The problem is that this testing isn’t standard of care yet, but everyone does agree that it will be at some point.
In January 2015, the federal government launched a 250 million Precision Medicine Initiative to help build a data base that stores information and to support research at the National Cancer Institute. That funding alone, however, isn’t nearly enough to usher in a new era of custom cancer care. What we need to do is have full data from all physicians which is the goal of the American Society of Clinical Oncology. ASCO recently announced it is creating a registry of patients who take drugs that are approved for a cancer other than the one for which they were cleared for by the FDA. We need to gather this information.
The problem is currently, less than 5% of the 1.6 million people diagnosed with cancer each year in Europe and the United States can take advantage of genetic testing. At most hospitals in this country this kind of testing is limited. If it is done there is always an out of pocket expense to the patient.
You need to have this revolutionary testing or you will never know how to attack your cancer. New sensitivity testing provides new insights revealing what actually works on your cancer. We provide the best medical protocols from all over the world with low dose metronomic chemotherapy, natural substances, and immunotherapies. If you would like more information please call us at (480) 860-2030.